CERE Investors Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. on behalf of investors who sold or held shares during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit covers individuals or entities that sold or held Cerevel common stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - Allegations include that Bain Capital and Pfizer orchestrated a secondary stock offering to allow Bain to acquire shares at a discounted price before AbbVie’s acquisition announcement [5] - The acquisition by AbbVie was announced at $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Legal Representation - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - A lead plaintiff must be appointed by June 3, 2025, to represent the interests of the class members [1][3]